In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Signs Up Another Oral Insulin Partner, Hedging Its Bets

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk places another oral insulin technology bet with Emisphere; expands partnership with Merrion beyond insulin.
Advertisement

Related Content

Looking For The New Lantus: Next-Gen Diabetes Hopefuls Defy Risks
Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars
For Some, Oral Insulin’s Allure Persists Despite Hurdles
For Some, Oral Insulin’s Allure Persists Despite Hurdles
India's Biocon Says Primary Endpoints Set For Oral Insulin May Have Been "Harsh"; Reinforces Goal To Develop Drug With Global Partner
Merrion, Novo Nordisk To Collaborate On Oral Insulin Analogues
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D
Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D

Topics

Advertisement
UsernamePublicRestriction

Register

PS071652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel